Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Neural Regulation01:37

Neural Regulation

39.7K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.7K
Regulated Protein Degradation02:58

Regulated Protein Degradation

7.5K
It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
7.5K
The Proteasome01:13

The Proteasome

961
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
961
Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

6.9K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
6.9K
Amyloid Fibrils03:03

Amyloid Fibrils

9.7K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
9.7K
Regulation of Expression at Multiple Steps01:23

Regulation of Expression at Multiple Steps

971
The gene expression in cells is regulated at different stages: (i) transcription, (ii) RNA processing, (iii) RNA localization, and (iv) translation. Transcriptional regulation is mediated by regulatory proteins such as transcription factors, activators, or repressors—these control gene expression by initiating or inhibiting the transcription of genes. Once a precursor or pre-mRNA is produced, it undergoes post-transcriptional modification, including 5' capping, splicing, and the...
971

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CTE-type tau filaments in Alzheimer's disease with co-morbid LATE-NC.

Acta neuropathologica·2026
Same author

ADAR2-Mediated RNA Editing Promotes TDP-43 Nuclear Export and Alters RNA Binding.

bioRxiv : the preprint server for biology·2026
Same author

Longitudinal Dynamics of Polyglutamine-Expanded ATXN3 in Biofluids of Spinocerebellar Ataxia Type 3.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

Isoform-specific steric zippers drive aberrant assembly and mislocalization of shortened TDP-43.

Science advances·2026
Same author

Cardiovascular Exercise Drives Neuroprotection in a Mouse Model of Spinocerebellar Ataxia 1 Via Rescue of Aberrant Splicing.

Annals of neurology·2026
Same author

Fluctuation-induced quenching of chaos in quantum optics.

Chaos (Woodbury, N.Y.)·2026

Related Experiment Video

Updated: Aug 15, 2025

Recombinant α- β- and γ-Synucleins Stimulate Protein Phosphatase 2A Catalytic Subunit Activity in Cell Free Assays
09:36

Recombinant α- β- and γ-Synucleins Stimulate Protein Phosphatase 2A Catalytic Subunit Activity in Cell Free Assays

Published on: August 13, 2017

6.8K

Ubiquilin-2 regulates pathological alpha-synuclein.

Stephanie S Sandoval-Pistorius1,2, Julia E Gerson1, Nyjerus Liggans1

  • 1Department of Neurology, University of Michigan, Ann Arbor, MI, 48109-2200, USA.

Scientific Reports
|January 7, 2023
PubMed
Summary
This summary is machine-generated.

Ubiquilin-2 (UBQLN2) regulates alpha-synuclein levels, particularly the pathological pS129 form, in Parkinson's disease models. UBQLN2 targets pS129 for degradation, suggesting its dysregulation contributes to disease toxicity.

More Related Videos

A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model
08:24

A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model

Published on: November 25, 2022

2.3K
Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains
09:27

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains

Published on: January 5, 2016

17.5K

Related Experiment Videos

Last Updated: Aug 15, 2025

Recombinant α- β- and γ-Synucleins Stimulate Protein Phosphatase 2A Catalytic Subunit Activity in Cell Free Assays
09:36

Recombinant α- β- and γ-Synucleins Stimulate Protein Phosphatase 2A Catalytic Subunit Activity in Cell Free Assays

Published on: August 13, 2017

6.8K
A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model
08:24

A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model

Published on: November 25, 2022

2.3K
Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains
09:27

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains

Published on: January 5, 2016

17.5K

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Protein Degradation

Background:

  • Alpha-synuclein (α-synuclein) aggregation and phosphorylation at serine 129 (pS129) are central to Parkinson's disease (PD) pathogenesis.
  • The protein quality control system's role in regulating α-synuclein, especially pathological forms, remains incompletely understood.
  • Ubiquilin-2 (UBQLN2) is found in synucleinopathies, but its direct function in α-synuclein regulation is unknown.

Purpose of the Study:

  • To investigate the role of Ubiquilin-2 (UBQLN2) in the regulation of α-synuclein, including its pathological pS129 isoform.
  • To determine if UBQLN2 directly impacts the degradation pathways of α-synuclein.
  • To assess the impact of Parkinson's disease on UBQLN2 solubility and function.

Main Methods:

  • Utilized cellular and mouse models of synucleinopathies.
  • Employed pharmacological proteasome inhibition.
  • Analyzed brain tissue from human Parkinson's disease patients and transgenic mouse models.

Main Results:

  • UBQLN2 was found to decrease overall α-synuclein levels, including the pS129 phosphorylated form.
  • Proteasome inhibition studies indicated UBQLN2 preferentially targets pS129 α-synuclein for degradation via the proteasome.
  • In human PD brains and α-synuclein transgenic mice, native UBQLN2 exhibited increased insolubility.

Conclusions:

  • UBQLN2 plays a direct role in regulating pathological forms of α-synuclein.
  • Dysregulation and reduced solubility of UBQLN2 in disease states may impair α-synuclein clearance, contributing to neurotoxicity.
  • These findings highlight UBQLN2 as a potential therapeutic target for Parkinson's disease and related synucleinopathies.